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ABSTRACT Vesicular stomatitis Indiana virus (VSIV), formerly known as vesicular
stomatitis virus (VSV) Indiana (VSVIND), is a model virus that is exceptionally sen-
sitive to the inhibitory action of interferons (IFNs). Interferons induce an antiviral
state by stimulating the expression of hundreds of interferon-stimulated genes
(ISGs). These ISGs can constrain viral replication, limit tissue tropism, reduce
pathogenicity, and inhibit viral transmission. Since VSIV is used as a backbone
for multiple oncolytic and vaccine strategies, understanding how ISGs restrict
VSIV not only helps in understanding VSIV-induced pathogenesis but also helps
us evaluate and understand the safety and efﬁcacy of VSIV-based therapies.
Thus, there is a need to identify and characterize the ISGs that possess anti-VSIV
activity. Using arrayed ISG expression screening, we identiﬁed TRIM69 as an ISG
that potently inhibits VSIV. This inhibition was highly speciﬁc as multiple viruses,
including inﬂuenza A virus, HIV-1, Rift Valley fever virus, and dengue virus, were
unaffected by TRIM69. Indeed, just one amino acid substitution in VSIV can gov-
ern sensitivity/resistance to TRIM69. Furthermore, TRIM69 is highly divergent in
human populations and exhibits signatures of positive selection that are consis-
tent with this gene playing a key role in antiviral immunity. We propose that
TRIM69 is an IFN-induced inhibitor of VSIV and speculate that TRIM69 could be
important in limiting VSIV pathogenesis and might inﬂuence the speciﬁcity
and/or efﬁcacy of vesiculovirus-based therapies.
IMPORTANCE Vesicular stomatitis Indiana virus (VSIV) is a veterinary pathogen that
is also used as a backbone for many oncolytic and vaccine strategies. In natural and
therapeutic settings, viral infections like VSIV are sensed by the host, and as a result
the host cells make proteins that can protect them from viruses. In the case of VSIV,
these antiviral proteins constrain viral replication and protect most healthy tissues
from virus infection. In order to understand how VSIV causes disease and how
healthy tissues are protected from VSIV-based therapies, it is crucial that we identify
the proteins that inhibit VSIV. Here, we show that TRIM69 is an antiviral defense that
can potently and speciﬁcally block VSIV infection.
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Most invading pathogens are sensed by the vertebrate host, ensuring that immunedefenses are appropriately deployed. Following sensing, a common outcome is
the secretion of type I interferons (IFNs) whose signaling results in the upregulation of
hundreds of IFN-stimulated genes (ISGs) (1, 2). Many ISG products interfere with viruses
directly, generating an antiviral state in stimulated cells that impedes the infection,
replication, or propagation of viruses (3–5). In addition, many ISGs are themselves
involved in pathogen sensing and signal transduction, placing cells in a heightened
state of alert whereby they are poised to detect invading pathogens (6). The IFN
response typically involves hundreds of ISGs, many of which have been regulated by
IFNs for hundreds of millions of years (1). Although the major role that IFNs play in
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constraining viral pathogenesis and viral colonization is well established, because IFN
responses involve so many ISGs, it is often unclear which individual gene products
inhibit a given virus.
Vesicular stomatitis Indiana virus (VSIV) is a virus that is mainly restricted to the
Americas, where it causes vesicular stomatitis, a disease that primarily affects ungulates,
and also rarely causes mild infections in humans (7–9). VSIV is transmitted by biting
insects and causes characteristic vesicular lesions at bite sites around the hooves,
mouth, nose, teats, and coronary bands (7). Although complications can occur, natural
VSIV infection is typically mild and rapidly resolved. In contrast, experimental VSIV
infection can be highly pathogenic and neurotropic in young mice (10).
In addition to being a notable veterinary pathogen, VSIV has been used extensively
as a model virus and has been integral to our understanding of vesiculovirus and
rhabdovirus biology. Notably, vesiculoviruses can be particularly sensitive to IFNs,
leading to their inclusion in the IFN unit deﬁnition assay (11). Indeed, type I IFNs likely
play a major role in limiting the severity of VSIV infections, and multiple ISGs have been
ascribed anti-VSV activity (4, 12–15).
Importantly, IFNs play a major role in constraining VSIV in vivo. Type I IFN receptor
(IFNAR) knockout (KO) mice succumb to doses of VSIV that are several orders of
magnitude lower than a lethal dose in wild-type (WT) mice (16). Moreover, while VSIV
is largely restricted to the central nervous system (CNS) in lethally infected WT mice,
VSIV colonizes multiple organs in IFNAR KO mice (16). Interestingly, it is likely that
multiple ISGs are involved in limiting the tissue tropism of VSIV. Speciﬁcally, it appears
that IFIT2 is crucial for preventing VSIV colonization of the brain, but it is not solely
responsible for limiting VSIV replication in other organs (15). Thus, other ISGs must play
key roles in limiting VSIV tissue tropism. Importantly, VSIV causes neurological disease
in multiple species following intracranial inoculation (17, 18), suggesting that the ability
of ISGs to prevent VSIV from initially accessing the CNS is the cornerstone in limiting
VSIV neuropathology across multiple species (19).
VSIV’s low pathogenicity in humans, its rapid replication, and ease of genetic
manipulation have made this virus the basis of multiple therapeutic strategies. For
example, VSIV can be modiﬁed to express antigens from heterologous viruses that can
be utilized as vaccine strategies (20). This approach has achieved recent notable success
in conferring protection from Ebola virus infection (21). Similarly, VSIV has been used as
the backbone of multiple oncolytic strategies (22). Just aa with natural VSIV infection,
IFNs and ISGs appear to be critical for preventing oncolytic viruses from invading
healthy tissues (23, 24) and could be critical determinants governing whether oncolytic
vesiculoviruses will be efﬁcacious (25). Furthermore, ISGs likely play a key role in
limiting the replication of VSIV-based vaccines and are an important safety feature of
this immunization strategy.
The key roles that ISGs play in constraining VSIV pathogenesis and limiting VSIV
replication (in natural infection, oncolytic therapies, and vaccine strategies) mean that
there is a need to better understand both how and which ISGs inhibit VSIV. Using
arrayed ISG expression screening, we identiﬁed the anti-VSIV activity of TRIM69, a
relatively poorly characterized TRIM protein. Through exogenous expression and
CRISPR/Cas9 knockout, we demonstrate that both exogenous and endogenous TRIM69
have potent anti-VSIV activity. Importantly, the inhibition is highly speciﬁc for VSIV as
multiple other viruses were not inhibited by TRIM69. Notably, TRIM69 shows strong
signatures of positive selection, and multiple common alleles circulate in human
populations. Interestingly, murine orthologues of TRIM69 had no detectable anti-VSIV
activity whereas rat TRIM69 possessed potent antiviral activity. We speculate that
TRIM69 could be an important ISG for protecting healthy tissues from VSIV and might
therefore limit VSIV pathogenesis and inﬂuence the speciﬁcity and efﬁcacy of
vesiculovirus-based therapeutic strategies.
(This article was submitted to an online preprint archive [26]).
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RESULTS
ISG expression screening reveals the anti-VSIV activity of TRIM69. We have
previously used arrayed ISG expression screening of human and rhesus macaque ISG
libraries to identify antiviral factors targeting a range of viruses (3, 5, 27). Although VSIV
has previously been subjected to a large-scale screen of 300 ISGs (4), we reasoned
that using larger libraries of arrayed ISGs might identify additional anti-VSIV effectors.
We recently expanded our human ISG library to include 500 ISGs, which can be used
in conjunction with our existing library of 300 rhesus macaque ISGs (5, 27) (Fig. 1A),
all of which are encoded by lentiviral vectors (Fig. 1B). In addition, we took advantage
of a single-cycle VSIV-green ﬂuorescent protein (VSIV-GFP) system (recombinant vesic-
ular stomatitis virus where the glycoprotein [G] has been deleted and replaced with
GFP [rVSVΔG-GFP], referred to herein as VSIV-GFP) to allow us to identify strong early
blocks to VSIV with high ﬁdelity (28). We ﬁrst transduced human MT4 cells with each
ISG-encoding lentiviral vector and then challenged these cells with VSIV-GFP, using a
dose whereby 30% of cells were infected (Fig. 1C). The level of VSIV-GFP infection in
the presence of each individual ISG was then quantiﬁed using ﬂow cytometry (Fig. 1C
and D). Strikingly, only three genes potently inhibited VSIV under these conditions:
macaque IFNB1, human Mx1, and human TRIM69. Although we identiﬁed only one
ortholog of each gene, we do not ascribe this to species-speciﬁc antiviral activity as
macaque TRIM69 and human IFNB1 were not present in these libraries. Moreover, the
FIG 1 Arrayed ISG expression screening reveals the potent anti-VSIV activity of TRIM69. (A) A schematic of the lSG libraries used herein. (B) A schematic of the
SCRPSY lentiviral vector (GenBank accession no. KT368137.1) used to deliver ISGs shown in panels C and D (one ISG per well of a 96-well plate). (C) A schematic
of the ISG screening pipeline used in panel D. (D) Normalized infection (median centered) of cells expressing different ISGs (each dot represents the observed
infection in the presence of a single ISG). The screen was executed once. (E) MT4 cells (modiﬁed to express doxycycline-inducible TRIM69) were incubated with
and without doxycycline for 24 h and then challenged with serially diluted GFP-encoding variants of VSIV for 16 h, inﬂuenza A virus (IAV) for 16 h, RVFV (Rift
Valley fever phlebovirus) for 48 h, or HIV-1 for 48 h prior to ﬁxation and enumeration of GFP-positive cells using ﬂow cytometry. Virus titrations were carried
out on at least two occasions, and typical results are shown. Mean values of experimental replicates are plotted, and error bars represent standard deviations.
(F) The same cells as used for the experiment shown in panel E were infected with unmodiﬁed (WT) VSIV, and infectivity/replication was quantiﬁed using TCID50.
The mean and standard deviation are plotted. Dox, doxycycline.
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isoform of macaque Mx1 included in the screen lacked 154 N-terminal residues relative
to the sequence of the human counterpart (that exhibited anti-VSIV activity), potentially
explaining the lack of inhibition conferred by the macaque variant. Importantly, TRIM69
was not identiﬁed in the previous ISG screen of VSIV as it was not present in the ISG
library used (4).
TRIM69 exhibits potent and highly speciﬁc antiviral activity. Because the anti-
VSIV activities of type I IFN and Mx1 are well documented (13, 16), we were immediately
struck by how potent the TRIM69-mediated inhibition of VSIV was in our initial screen
(Fig. 1D). At the time that these experiments were carried out, TRIM69 had not been
ascribed any antiviral activity, so we examined the ability of doxycycline-inducible
TRIM69 to inhibit a small panel of viruses. Notably, while VSIV-GFP infection was
reduced by 100-fold by TRIM69, the other viruses in our panel [inﬂuenza A virus
A/Puerto Rico/8/1934 (H1N1) (PR8), Rift Valley fever phlebovirus (RVFV 35/74), and
HIV-1 (NHG)] were unaffected by TRIM69 expression (Fig. 1E). It is well documented that
many TRIM proteins are involved in antiviral signaling, which can often be triggered by
exogenous expression (5, 29–31). Moreover, exogenous or endogenous expression of
many ISGs can promote cell death (32). However, the highly speciﬁc antiviral activity of
TRIM69 against VSIV suggests that the antiviral mechanism does not involve global
processes such as cellular toxicity or the induction of a polygenic antiviral state.
Interestingly, a VSV-G (glycoprotein) pseudotyped variant of HIV-1 that does not
express an HIV-1 envelope glycoprotein and was decorated with a VSV-G envelope
derived from VSIV was also insensitive to TRIM69-mediated inhibition (Fig. 1E). This
suggests that inhibition of VSIV by TRIM69 occurs after viral entry and that the VSIV
glycoprotein is not directly targeted by TRIM69. Importantly, unmodiﬁed wild-type
replication-competent VSIV was also potently inhibited by TRIM69 (Fig. 1F).
Endogenous TRIM69 is IFN inducible and potently inhibits VSIV. We have
previously used comparative transcriptomics to study the IFN response in a variety of
species (1). Meta-analysis of these data indicated that TRIM69 expression was upregu-
lated 10-fold following IFN stimulation in primary human ﬁbroblasts (Fig. 2A). Simi-
larly, TRIM69 has been previously identiﬁed as an ISG in multiple studies and is typically
induced between 2- and 10-fold by type I IFNs (2, 33). To examine whether the
endogenous protein exhibited antiviral activity, we knocked out TRIM69 using CRISPR/
Cas9 in diploid CADO-ES1 cells (34). We selected CADO-ES1 cells for these experiments
as existing transcriptomics data suggested that TRIM69 was efﬁciently expressed in
these cells (EMBL-EBI Expression Atlas [https://www.ebi.ac.uk/gxa/home]). TRIM69 knock-
out (KO) single-cell clones were derived, and the KO was conﬁrmed by sequencing the
genetic lesions. In accordance with the IFN-sensitive nature of vesiculoviruses, IFN
treatment potently blocked VSIV infection in “no-guide” control clones (by 10,000-
fold) (Fig. 2B and D). In striking contrast, when TRIM69 was knocked out, the protective
effect of IFN was markedly reduced (by 300-fold). This indicates that endogenous
TRIM69 appears to play a major role in the anti-VSIV effects of IFN. Furthermore, the
TRIM69 anti-VSIV activity was again speciﬁc as the magnitude of HIV-1 inhibition was
largely similar in the presence or absence of TRIM69 (Fig. 2C and E). Because CADO-ES1
cells do not support efﬁcient HIV-1 infection, a pseudotyped HIV-1-based lentiviral
vector (CSGW) was used for these experiments.
Not all TRIM69 isoforms confer antiviral activity. Because alternative splicing can
produce divergent variants of antiviral factors, these spliced isoforms can exhibit
differential antiviral activity. In the case of another TRIM protein, TRIM5, the spliced
isoforms have been informative in understanding the mechanism of TRIM5’s antiviral
activity (35). We therefore considered whether all isoforms of TRIM69 conferred anti-
VSIV activity. We cloned the ﬁve human TRIM69 isoforms listed on ENSEMBL, and we
considered their activity in our doxycycline-inducible system. Using this strategy, we
were able to detect expression of only isoforms A and B by Western blotting (Fig. 3A)
even though the polyclonal antibody should recognize all isoforms. The only variant
that conferred anti-VSIV activity was the longest isoform, isoform A (Fig. 3B to D), which
Rihn et al. Journal of Virology
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FIG 2 IFN-stimulated endogenous TRIM69 has potent anti-VSIV activity. (A) TRIM69 expression in primary human ﬁbroblasts following 4 h in the presence or
absence of 1,000 units/ml of universal IFN. The transcriptomes were deﬁned using transcriptome sequencing (RNA-seq) (1), and the meta-analyzed TRIM69
expression in counts per million (CPM) is plotted. (B) VSIV-GFP inhibition was measured in CADO-ES1 cells in which TRIM69 expression was knocked out using
CRISPR/CAS9 or in CADO-ES1 cells that were transduced with no-guide controls. Titrated challenges were used to determine the titer, at 16 h postinfection,
in the presence and absence of IFN stimulation and to correspondingly calculate the fold inhibition. Fold inhibition was calculated from three experiments; each
experiment is represented by the circles (each circle displays a mean of fold inhibition calculated from three titration points in the linear range), and the mean
and standard deviation are plotted. The fold rescue in inhibition (332x) is indicated by the vertical line. (C) The experiment was performed as described for panel
B using a single-cycle HIV-1 reporter system (CSGW) (65). (D) The VSIV-GFP titration data (each curve represents an individual clone) in the presence and absence
of IFN treatment, as described for panel B, are presented. (E) As described for panel D, the HIV-1 (CSGW) titration data from panel C are shown.
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potently inhibited VSIV-GFP infection. Notably, isoform B was abundantly expressed
(Fig. 3A), and we thus concluded that this isoform has no anti-VSIV activity. This
suggests that the RING domain (or ﬂanking sequence) is critically required for anti-VSIV
activity or the correct folding or multimerization of TRIM69. Although we were unable
to express or detect isoforms C, D, and E, because these isoforms also lack the
N-terminal residues missing in isoform B, we ﬁnd it unlikely that they possess anti-VSIV
activity.
As well as lacking antiviral activity, shorter isoforms of the TRIM5 protein can form
heteromultimers with TRIM5 and act as dominant negative inhibitors of endogenous
and exogenous TRIM5-mediated restriction (35). We thus examined whether TRIM69
isoform B might similarly inhibit the anti-VSIV activity of isoform A. When TRIM69
(isoform A) was constitutively expressed, it conferred potent protection from VSIV-GFP
infection (Fig. 3E), and this protection was further enhanced by the presence of
inducible myc-tagged TRIM69 (Fig. 3E). In contrast, constitutively expressed TRIM69
isoform B had negligible effect on the ability of isoform A to inhibit VSIV (Fig. 3E),
despite being abundantly expressed (Fig. 3F). Thus, although TRIM69 isoform B has no
detectable antiviral activity, it does not appear to interfere with the ability of isoform
A to block VSIV. It is therefore likely that heteromultimers between isoform A and
isoform B either cannot form or are competent to restrict VSIV.
FIG 3 TRIM69 isoform A, but not isoform B, restricts VSIV. (A) Western blot analysis of TRIM69 expression (isoforms A to E) using a polyclonal anti-TRIM69
antibody (PA5-12215 [ThermoFisher], raised against TRIM69 residues 336 to 365, which are present in all isoforms). (B) MT4 cells were modiﬁed to express
Myc-TagRFP (where RFP is red ﬂuorescent protein) in a doxycycline-inducible fashion. An illustration of TagRFP is depicted above typical titration curves of
VSIV-GFP, the VSIV-GFP titers (16 h postinfection), and Western blot analysis of Myc-TagRFP expression (24 h postinduction) in the presence and absence of
doxycycline treatment. (C) MT4 cells were modiﬁed to express myc-TRIM69 isoform A in a doxycycline-inducible fashion. An illustration of TRIM69 isoform A
(predicted mass, 57 kDa) is depicted above typical titration curves of VSIV-GFP and the VSIV-GFP titers of inducible TRIM69 isoform A expression in the
presence and absence of doxycycline treatment. (D) Data are as described in panel C but for isoform B (predicted mass, 39 kDa). (E) Cells described in the
legend of panel C were modiﬁed to constitutively express TRIM69 isoform A, isoform B, or TagRFP (by LHCX transduction). The titer of VSIV-GFP was determined
in the presence and absence of doxycycline-inducible myc-TRIM69 isoform A. (F) Western blot analysis of the cells used in the experiment shown in panel E.
In all cases, virus titrations were carried out on at least two occasions, and typical results are shown. Mean titers and standard deviations are plotted based on
at least three doses (in the linear range).
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Multiple TRIM69 alleles circulate in human populations, and TRIM69 exhibits
strong signatures of positive selection. We next analyzed structural variation at the
TRIM69 locus in human populations, using data from the 1000 Genomes Project
collated by ENSEMBL (36). Interestingly, multiple TRIM69 alleles circulate at high
frequencies in human populations. Surprisingly, the human TRIM69 variant NM_182985
(NCBI Reference Sequence) is only the third most common human TRIM69 allele,
present at frequencies of 4% (European) to 17% (South Asian) in human popula-
tions. In light of this, we examined the ability of all the major TRIM69 alleles (with a
frequency 5% in at least one population) to inhibit a small panel of vesiculoviruses
(Fig. 4). We cloned the seven main alleles into our doxycycline-inducible expression
system (Fig. 4A to C) and challenged these cells with a small panel of vesiculoviruses
(Fig. 4D to G). In spite of the amino acid variation (Fig. 4A), all seven major alleles
conferred potent protection from VSIV infection (Fig. 4E). Although some variation in
the magnitude of protection was observed, we attributed this to slight variations in
TRIM69 expression levels, as opposed to variation in the anti-VSIV activities of the
different alleles (Fig. 4C). Upon further viral challenges, TRIM69 again exhibited exqui-
site antiviral speciﬁcity as none of the TRIM69 human alleles inhibited either VSV New
Jersey (VSNJV) (Fig. 4F) or Chandipura virus (37) (CHNV-GFP) (Fig. 4G), both of which are
closely related to VSIV (Fig. 4D).
Since multiple TRIM69 alleles currently circulate in human populations and because
antiviral TRIM proteins can possess strong signatures of positive selection (38), we
conducted positive-selection analysis of TRIM69 sequences from primates. We retrieved
and aligned the TRIM69 coding region from 18 primate species representing 40
FIG 4 Multiple TRIM69 alleles circulate in human populations. (A) The amino acid substitutions of the most common TRIM69 alleles (as determined via the 1000
Genomes Project). (B) The allelic frequency of the major alleles by geographic region (as determined via the 1000 Genomes Project). (C) MT4 cells were modiﬁed
to express the seven most common TRIM69 alleles in a doxycycline-inducible fashion. Western blot analysis of myc-TRIM69 expression in cells was performed
with and without 24 h of doxycycline treatment. (D) The redrawn phylogeny of common vesiculoviruses (80) is shown (asterisks represent bootstrap proportions
higher than 85%). (E to G) The cells described in the legend of panel C were used to examine the ability of divergent TRIM69 alleles to inhibit VSIV-GFP (E),
VSNJV (F), and CHNV-GFP (G). Virus titrations were carried out on at least two occasions, and typical results are shown. Mean titers and standard deviations are
plotted based on at least three doses (in the linear range).
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million years of divergent evolutionary pressures (39). Using the maximum likelihood
approach in PAML (40), we tested whether models that permit positive selection on
individual codons (ratio of nonsynonymous to synonymous changes [dN/dS] of 1)
were a better ﬁt to these data than models that do not allow positive selection. In each
case, permitting sites to evolve under positive selection gave a better ﬁt (Fig. 5A and
B), with a high proportion of codons exhibiting dN/dS values greater than 1 (32.8% with
an average dN/dS of 1.9). These analyses identiﬁed six residues exhibiting relatively
strong signatures of positive selection (Fig. 5A and B). One of the sites identiﬁed using
this approach (S404) is within the SPRY domain (the domain that forms the host-
pathogen interface that deﬁnes the antiretroviral speciﬁcity of TRIM5 [38]). These
analyses suggest that while the majority of sites (67.2%) in TRIM69 have evolved under
purifying selection (in order to maintain the overall structure and function of TRIM69),
positive selection has likely occurred at speciﬁc sites, perhaps inﬂuencing the antiviral
activity of TRIM69 (38).
Based on the signatures of positive selection at the TRIM69 locus in primates, we
hypothesized that divergent TRIM69 proteins might exhibit divergent antiviral speci-
ﬁcities. We therefore cloned a variety of TRIM69 orthologs from a selection of species
(including primates and a variety of other mammals) into our doxycycline-inducible
expression system. Similar to human TRIM69, orthologs from rhesus macaques, rats,
cows, alpacas, dogs, ferrets, and horses all potently inhibited VSIV infection (Fig. 5C).
Although the magnitude of inhibition was variable, we attributed the majority of this
variability to different TRIM69 expression levels (Fig. 5C). Strikingly, murine TRIM69 did
not inhibit VSIV, despite being expressed at higher levels than multiple inhibitory
orthologs (Fig. 5C). Furthermore, the anti-VSIV activity of TRIM69 appears to have been
lost in the Mus genus, as TRIM69 orthologs from Mus caroli and Mus pahari were also
noninhibitory, whereas rat TRIM69 potently inhibited VSIV (Fig. 5D). This is not simply
due to the murine orthologs lacking speciﬁc cofactors/interactions within human cells,
as stable expression of murine TRIM69 (Mus musculus) in mouse cells indicated that
murine TRIM69 still possessed no apparent anti-VSIV activity (Fig. 5E). Crucially, murine
TRIM69 was abundantly expressed in these cells, and human TRIM69 conferred potent
protection from VSIV infection when expressed at similar levels in the identical murine
background (Fig. 5E and F). Thus, while murine cells support TRIM69-mediated anti-
VSIV activity, all tested murine orthologs of TRIM69 have lost the ability to inhibit VSIV.
We also challenged the species variants of TRIM69 with related vesiculoviruses
(VSNJV and CHNV), but none of the orthologs considered possessed substantial anti-
viral activity against these viruses (Fig. 5G and H).
In light of the positive-selection analysis and species-dependent activity of TRIM69,
we compared the murine TRIM69 amino acid sequence to sequences of the restrictive
human and rat TRIM69 variants (Fig. 6). While human and mouse TRIM69 sequences
were relatively well conserved (79% identity), the rat and mouse variants (which were
the closest orthologs we tested that displayed differential activity against VSIV), ap-
peared highly similar, differing at only 38 amino acid positions (92% identity). Although
site-speciﬁc signatures of positive selection were detected in TRIM69, all of the signa-
ture sites were conserved between rats and mice (Fig. 6). Thus, the genetic basis of the
differential anti-VSIV activity observed in rodent TRIM69 variants is currently unknown.
The VSIV phosphoprotein confers sensitivity/resistance to TRIM69. The short
generation times inherent to the lifecycles of most viruses mean that resistance to
inhibition can be rapidly selected in vitro (5, 27, 41, 42). Approaches using in vitro
evolution can rapidly identify antiviral sensitivity/resistance determinants in viruses
targeted by antiviral factors (41, 43). We used a diverse swarm of replication-competent,
full-length (FL) VSIV-GFP (44) that had been propagated in mammalian cells. This
parental virus stock was potently inhibited by TRIM69 following overnight infection
(Fig. 7A). We used this virus to inoculate a culture expressing TRIM69, using a dose in
which 1% of cells were GFP positive following overnight incubation. Four days later,
VSIV had begun to overwhelm this culture, and the supernatant was ﬁltered and
Rihn et al. Journal of Virology
October 2019 Volume 93 Issue 20 e00951-19 jvi.asm.org 8
 o
n
 O
ctober 28, 2019 at SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
FIG 5 TRIM69 exhibits signatures of positive selection, and anti-VSIV activity has been lost in the Mus lineage. (A) The diagram at top illustrates
the conserved domains of TRIM69 based on the Conserved Domains Database (CDD), version 3.16, from NCBI. The bar chart at bottom
(Continued on next page)
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transferred to a new culture (also induced to express TRIM69). In this second passage,
VSIV replicated far more efﬁciently in the presence of TRIM69, suggesting that resis-
tance had emerged. Such rapid acquisition of resistance is a documented property of
VSIV populations, and VSIV ﬁtness has been previously shown to increase 1,000-fold
in a single passage (within a new cellular environment) (45). We titrated the ﬁltered
supernatant containing the TRIM69-passaged swarm, in the presence and absence of
TRIM69, and observed that VSIV had been selected to resist TRIM69 inhibition (Fig. 7A).
We sequenced the viral population and observed four substitutions that had been
selected to near uniformity in the viral swarm (Fig. 7B and C). These substitutions
included two synonymous changes and two nonsynonymous substitutions. Because we
had previously observed that the VSV-G protein was not targeted by TRIM69 when used
to pseudotype HIV-1 (Fig. 1E), we reasoned that one substitution, E92K in VSIV-G, was
unlikely to confer resistance to TRIM69. This left only one nonsynonymous substitution,
D70Y, located in the VSIV phosphoprotein (P protein) that might confer TRIM69
resistance. We mutated this residue in isolation in the FL VSIV-GFP plasmid background
and rescued the parental and D70Y mutant viruses. While the rescued parental virus
was potently inhibited by TRIM69, the P protein D70Y mutant was completely insen-
sitive to inhibition by TRIM69 (Fig. 7D). Thus, the VSIV P protein is the genetic target of
TRIM69 and can determine sensitivity or resistance to TRIM69. Moreover, just a single
amino acid within the P protein can determine TRIM69 sensitivity. We next considered
the variation at position 70 in VSIV sequences deposited in GenBank. Interestingly, VSIV
was uniformly aspartic acid at position 70 (Fig. 7E), suggesting that the D70Y escape
mutant either cannot thrive in vivo or that TRIM69 does not exert enough pressure to
provide a selective advantage to this variant (within these sequences). Importantly,
FIG 5 Legend (Continued)
represents the dN/dS values of the sites with positive selection. The six sites with statistically signiﬁcant positive selection (PAML M8 with Bayes
Empirical Bayes [BEB], P 0.9) are shown in red. The phylogenetic relationship between the 18 sequences spanning the hominoids is shown
on the left, with the regions of the alignment with statistically signiﬁcant positive sites shown numbered on the right. (B) The results of the
chi-square test comparing the PAML models is shown in the table along with the proportion of sites under positive selection and the average
dN/dS for those sites. (C) MT4 cells were modiﬁed to express myc-TRIM69 orthologs from multiple species in a doxycycline-inducible fashion.
Western blot analysis of TRIM69 expression in cells with and without 24 h of doxycycline treatment is shown beneath the titers of VSIV-GFP
(16 h postinfection) in the presence and absence of doxycycline treatment. (D) The experiment as described for panel C, examining TRIM69 from
rat and divergent mice. (E) NIH 3T3 cells were modiﬁed to stably express TagRFP or human or mouse TRIM69 (LHCX) before being infected with
serially diluted VSIV-GFP. (F) Western blot analysis of TRIM69 expression in the cells from the experiment described if panel E. (G to H) The cells
from the experiment described in panel C were used to determine the titers of VSNJV (G) and CHNV-GFP (H). In all cases, virus titrations were
carried out on at least two occasions, and typical results are shown. Mean and standard deviations are plotted, and titers are based on at least
three doses (in the linear range). LRT, likelihood ratio test.
FIG 6 Amino acid alignment of human, rat, and mouse TRIM69 proteins. An amino acid alignment of TRIM69 proteins from human (Homo sapiens, GenBank
accession no. NM_182985), rat (Rattus norvegicus, NM_001013160), and mouse (Mus musculus, NM_080510), aligned using ClustalW, is shown. Protein domains
are highlighted (based on Conserved Domains Database [CDD], version 3.16, from NCBI), and positions where the murine variant differs from human and rat
are highlighted in bold type. Sites identiﬁed as positively selected in primates are highlighted with a star (). The arrow denotes the start of isoform B (preceded
by amino acids one and two [ME] from the ﬁrst coding exon).
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antiviral factors that target highly conserved viral peptides are more likely to form an
effective antiviral defense.
TRIM69 inhibits VSIV but not DENV-2. During the preparation of the manuscript,
it was reported that TRIM69 is an ISG that targets dengue virus type 2 (DENV-2) through
an interaction with NS3 that targets NS3 for degradation (33). This TRIM69-mediated
degradation of NS3 interrupts the life cycle of DENV-2 (33). This observation was of
immediate interest to us as it is unusual for an antiviral factor to speciﬁcally target
viruses as divergent as DENV-2 (a positive-sense ssRNA virus) and VSIV (a negative-
sense ssRNA virus). Moreover, murine TRIM69, which is inactive against VSIV, was
reported to inhibit DENV-2 (33), suggesting that species variants of TRIM69 might have
divergent antiviral speciﬁcities. We thus compared the ability of TRIM69 to inhibit
FIG 7 The VSIV phosphoprotein is a genetic susceptibility/resistance determinant of TRIM69 anti-VSIV activity. (A) Serially diluted infection of MT4 cells modiﬁed
to express doxycycline-inducible human TRIM69 with either parental FL-VSIV-GFP or FL-VSIV-GFP passaged twice (P2) in the presence of human TRIM69 is
shown. (B) The passaged and parental swarms were sequenced, and the listed changes were selected to near uniformity in the passaged population. (C)
Sequencing chromatograms of directly sequenced PCR products ampliﬁed from the reverse-transcribed viral swarms are shown. (D) Titrated infection of the
cells described for panel A with the parental virus and the D70Y (P) mutant FL-VSIV-GFP, rescued in parallel. In all cases, virus titrations were carried out on
at least two occasions, and typical results are shown. Mean and standard deviation are plotted. (E) A WebLogo (weblogo.berkeley.org) sequence logo of the
region of the phosphoprotein containing D70 from an alignment of 14 nonredundant protein sequences of VSIV compiled from 50 sequences retrieved from
GenBank.
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DENV-2 and VSIV in the same experiment. Because Vero cells are susceptible and
permissive to both DENV-2 and VSIV, we selected these cells as the background for our
experiments and generated Vero cells that stably expressed human, rat, or mouse
TRIM69 and infected these cells with a titrated challenge of DENV-2 or VSIV-GFP. We
used the New Guinea C strain of DENV-2 as this strain was previously reported to be
inhibited by TRIM69 (33). Unexpectedly, DENV-2 produced in either mammalian or
insect cells was not inhibited by TRIM69 under these conditions (Fig. 8A to D). In
contrast, VSIV was potently inhibited by human and rat, but not mouse, TRIM69 in
parallel experiments (Fig. 8E and F).
Because the previously published work had not speciﬁcally investigated exogenous
TRIM69 expression in Vero cells, we examined whether TRIM69 expression in HEK 293T
cells would induce the degradation of transfected NS3 but not NS3 K104R (in order to
recapitulate the published observations) (33). Surprisingly, TRIM69 had no effect on NS3
expression levels (Fig. 8G). In contrast, VSIV was potently blocked in parallel experi-
ments using the equivalent cells (Fig. 8H). We conclude that DENV-2 is not always
inhibited by TRIM69, even under conditions where TRIM69 exhibits substantial antiviral
activity against VSIV.
The anti-VSIV activity of TRIM69 is not dependent upon IFN signaling or E3 Ub
ligase activity. TRIM69 has a RING domain that is predicted to have E3 ubiquitin (Ub)
FIG 8 TRIM69-mediated inhibition of DENV-2 was not detected under conditions that restrict VSIV. Vero cells were modiﬁed to stably express human, rat, and
mouse TRIM69 or were transduced with the corresponding empty vector (SCRPSY). Where indicated, cells transduced with the empty vector were also
pretreated with 1,000 units of IFN-. Cells were then challenged with DENV-2 propagated in Vero cells (mammalian DENV-2) (A and B) or with DENV-2 produced
from Aedes albopictus C6/36 cells (insect DENV-2) (C and D). At 48 h after infection, cells were ﬁxed and stained for DENV-2 infection, and infected foci were
imaged (representative images are shown panels B and D) and enumerated (A and C) using a Celigo imaging cytometer. (E and F) As described in the legend
for panels A to D, Vero cells were infected with FL-VSIV-GFP, ﬁxed, and analyzed 16 h after infection. (G) HEK 293T cells were modiﬁed to stably express human
TRIM69 or were transduced with the corresponding empty vector (SCRPSY). Empty () and TRIM69-expressing () cells were transfected with DENV-2 NS3,
DENV-2 NS3 K104R, or empty expression plasmids, and NS3 expression was analyzed 48 h later using Western blotting. (H) In parallel with the experiment shown
in panel G, functional TRIM69 expression in equivalent HEK 293T cells was assessed by titrated infection with VSIV-GFP. In all cases, virus titrations were carried
out on at least two occasions, and typical results are shown. Means and standard deviations are plotted.
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ligase activity. Moreover, proteasomal degradation has previously been reported to be
involved in the TRIM69-mediated inhibition of DENV-2 (33). In addition, TRIM69 isoform
B (which lacks a RING domain) possesses no anti-VSIV activity (Fig. 3C). We therefore
considered whether inhibiting proteasomal degradation might affect TRIM69 antiviral
activity. As a less toxic alternative to the proteasome inhibitor MG132, we used
bortezomib (Bort), an inhibitor of the 26S proteasome, which is also licensed for clinical
use (46, 47). In order to validate the efﬁcacy of inhibition, we transduced cells with a
lentiviral vector encoding ubiquitin fused to GFP. This fusion protein is rapidly de-
graded, and GFP expression is not visible under normal culture conditions (Fig. 9A and
B). However, when the 26S proteasome was inhibited by bortezomib treatment,
abundant GFP expression was visible, suggesting that proteasomal inhibition was
efﬁcient in our culture system. In parallel experiments, we considered the ability of
proteasome inhibition to inﬂuence TRIM69-mediated restriction of VSIV. When normal-
FIG 9 TRIM69-mediated antiviral activity does not require the proteasome or IFN signaling. (A) Phase-contrast and epiﬂuorescence images (EVOS FL microscope)
of unmodiﬁed MT4 cells or MT4 cells modiﬁed to express Ub-G76VGFP in the presence or absence of 50 nM bortezomib (proteasome inhibitor). (B) An illustration
of Ub-G76VGFP. (C and D) MT4 cells modiﬁed to express inducible Myc-TagRFP or myc-TRIM69 (human) were treated or not treated with doxycycline (24 h) before
being infected with VSIV-GFP (16 h) in the presence or absence of 50 nM bortezomib. Normalized titers are shown in panel C of the titration curves shown in
panel D. (E and F) The same experiment as described for panels C and D, but examining VSIV-GFP in the presence of inducible myc-TRIM69 with or without
2 M ruxolitinib (JAK1/2 inhibitor). Normalized titers are shown in panel F of the titration curves shown in panel E. (G) Phospho-STAT1 expression in the
presence and absence of 2 M ruxolitinib incubated for 24 h in the presence or absence of 1,000 units of IFN- was examined in MT4 cells (in the presence
or absence of doxycycline-inducible myc-TRIM69) and measured in parallel with the cells used in the experiment shown in panel E. In all cases, virus titrations
were carried out on at least two occasions, and typical results are shown. Means and standard deviations are plotted.
TRIM69 Inhibits VSIV Journal of Virology
October 2019 Volume 93 Issue 20 e00951-19 jvi.asm.org 13
 o
n
 O
ctober 28, 2019 at SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
ized to infection in the absence of TRIM69, proteasomal inhibition appeared to partially
rescue the restriction of VSIV (Fig. 9C). However, bortezomib treatment caused notice-
able toxicity in these experiments, consistent with bortezomib’s proapoptotic and
anti-tumor cell growth properties (47). Visual inspection of the titration curves indicated
that the majority of the rescue was due to reduced VSIV infection in control cells (in the
presence of bortezomib), as opposed to proteasomal inhibition actually enhancing
infection in the presence of TRIM69 (Fig. 9D). Importantly, TRIM69 potently restricted
VSIV (50-fold) in the presence of efﬁcient proteasome inhibition, indicating that
proteasomal degradation is not necessary for effective TRIM69-mediated restriction.
Many TRIM proteins are involved in antiviral signaling and appear to have antiviral
activity because their exogenous expression promotes or potentiates a polygenic
antiviral state (30, 31). Although the observation that most viruses escape inhibition by
TRIM69 suggests that a polygenic response is not involved, we investigated whether
TRIM69 could inhibit VSIV in the absence of JAK-STAT signaling. We therefore used the
Janus kinase (JAK) inhibitor ruxolitinib to block interferon signaling in TRIM69-
expressing cells (48). We then examined the ability of TRIM69 to block VSIV infection in
the absence of IFN signaling. As with bortezomib, some toxicity was observed, and
ruxolitinib slightly reduced the level of infection in the absence of TRIM69 (Fig. 9E and
F). Thus, the majority of the apparent 7-fold rescue (Fig. 9F) was caused by reduced
infection in the absence of TRIM69 (as opposed to ruxolitinib solely enhancing infection
in the presence of TRIM69). However, in contrast to bortezomib, ruxolitinib did mod-
estly increase the amount of VSIV infection in the presence of TRIM69 (increasing the
titer 2.5-fold) (Fig. 9E). Importantly, the ruxolitinib treatment effectively blocked IFN
signaling, and no phosphorylated STAT1 was detectable following IFN treatment in the
presence of ruxolitinib (Fig. 9G). Notably, TRIM69 expression alone was insufﬁcient to
trigger the phosphorylation of STAT1 (Fig. 9G), and TRIM69 potently blocked VSIV
(20-fold) in the presence of ruxolitinib. Thus, IFN signaling is not necessary for TRIM69
to inhibit VSIV (although JAK-STAT signaling might modestly enhance this inhibition).
DISCUSSION
Although vesiculoviruses can be particularly sensitive to IFN-induced inhibition, the
speciﬁc ISGs that mediate the anti-VSIV activity of IFNs (and how this inhibition is
achieved) have not yet been fully deﬁned. Here, we show that one ISG, TRIM69, can
potently and speciﬁcally inhibit VSIV. Moreover, the high degree of speciﬁcity of this
inhibition overwhelmingly suggests that this inhibition is direct. TRIM69 potently
blocked VSIV, whereas other vesiculoviruses (and more divergent RNA viruses) were
entirely resistant. Furthermore, the inhibition of VSIV appeared to be remarkably
speciﬁc as a single substitution conferred complete resistance to TRIM69. Thus, al-
though we cannot exclude the possibility that TRIM69 expression elicits some kind of
antiviral signaling, such a signaling event would have to be independent of protea-
somal degradation and JAK-STAT signaling and also result in an outcome that specif-
ically targeted VSIV. Therefore, the more parsimonious explanation is that TRIM69, or a
complex containing TRIM69, directly targets VSIV (and interferes with the virus life
cycle). This potentially adds TRIM69 to an expanding list of directly antiviral TRIM
proteins that includes the classical restriction factors TRIM5 (35) and PML (49). None-
theless, inhibition of IFN signaling modestly rescued VSIV infection, and TRIM69 KO
slightly reduced the IFN-induced inhibition of HIV-1. Thus, it is possible that TRIM69
might also play a signaling role analogous to the signaling capacity of established
directly antiviral factors such as TRIM5, TRIM21, and tetherin (50–52).
Perhaps the most surprising aspect of the highly speciﬁc anti-VSIV activity of TRIM69
was that DENV-2, previously reported to be inhibited by TRIM69 (33), was not inhibited
in our experiments. Importantly, this lack of TRIM69 sensitivity was observed while
parallel cultures (of the equivalent cells) ﬁercely resisted VSIV infection. There are many
possible explanations for these apparently contradictory observations. The most likely
explanation is that due to the highly speciﬁc nature of TRIM69-mediated inhibition,
some aspect of the virus strain, cellular background, or method used led to DENV-2
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appearing insensitive to inhibition (in our experiments). We were careful to use the
same strain as used previously (speciﬁcally, the New Guinea C strain, which we obtained
from Public Health England). We conﬁrmed the presence of the TRIM69-sensitive lysine
(at position 104 of NS3) in our virus stocks, and more work will be required to
understand why we did not observe DENV-2 inhibition in the face of antiviral TRIM69.
Importantly, with both VSIV and DENV-2, a single amino acid substitution conferred
resistance to TRIM69. Moreover, we considered only a single human allele (allele 3),
which differs at two residues from the variant used previously (GenBank accession no.
AY305385.1) (33, 53). Thus, seemingly minor differences in viral strains could easily
reconcile these apparently contradictory observations.
Although we do not know how TRIM69 impedes VSIV, the block must occur
relatively early in the viral life cycle. TRIM69 is able to block VSIV prior to the expression
of GFP, which in the case of the rVSVΔG-GFP system is encoded in place of the VSV-G
protein. Thus, the TRIM69-mediated block must occur at a step prior to translation of
VSV-G subgenomic RNA (sgRNA). In the absence of direct evidence, the D70Y mutation
in the VSIV phosphoprotein does provide some potential mechanistic clues. Impor-
tantly, D70 is present in a region of VSV-P that is heavily phosphorylated (phosphor-
ylation of residues 60, 62, and 64 has been described previously) (54). Phosphorylation
of these sites has been proposed to be important in P protein dimerization and
interaction with the L protein (large polymerase protein) (55–59), and phosphorylation
of this region is essential for functional RNA-dependent RNA polymerase activity (60).
Because tyrosine residues are known to be phosphorylated in the VSV-P protein (61), it
is therefore tempting to speculate that a tyrosine at position 70 could be phosphory-
lated and that this phosphorylation somehow overcomes the block mediated by
TRIM69. A speculative mechanism that involves TRIM69-mediated inhibition of VSIV
RNA-dependent RNA polymerase activity (by inhibiting the association of P and L
proteins), preventing subgenomic RNA transcription, would be entirely consistent with
the early block described herein.
Although TRIM69 isoform B (which lacks the RING domain) does not possess
anti-VSIV activity, proteasomal inhibition was unable to rescue VSIV infectivity. Thus, it
is unclear whether functional E3 ubiquitin ligase activity is required to inhibit VSIV.
Importantly, isoform B is 30% shorter than isoform A, and it is possible that such a
large deletion perturbs the tertiary or quaternary structure of TRIM69. Such an inability
to form multimers could simultaneously explain why isoform B is both inactive and
lacks dominant negative activity. More work will be required to understand the role
that E3 ubiquitin ligase activity plays in TRIM69’s immune role.
The N-terminal regions of vesiculoviral P proteins are relatively divergent, providing
a possible explanation for the observed insensitivity of VSNJV and CHNV to TRIM69.
Thus, examining the more closely related Morreton virus (MORV), vesicular stomatitis
Alagoas virus (VSAV), Cocal virus (COCV), or Maraba virus (MARV) might identify more
viruses which are sensitive to TRIM69 and potentially identify further evidence of
species speciﬁcity. Notably, after analyzing 50 VSIV sequences (deposited in GenBank),
we did not observe a tyrosine at position 70 of VSIV-P in any VSIV sequences. This
suggests that if TRIM69 substantially inhibits VSIV in vivo, the D70Y mutation must be
deleterious for some other reason and is therefore negatively selected (despite con-
ferring resistance to TRIM69). Potential explanations include a reduction in replicative
ﬁtness or sensitization to other immune processes. Although we have not directly
compared the replicative ﬁtness of the D70Y mutant to that of the parental virus, virus
preps of this mutant have slightly lower titers (less than a 5-fold reduction [our
unpublished observations]), providing a possible explanation as to why this mutant was
not observed in reported VSIV sequences.
Our failure to identify any viruses other than VSIV that were inhibited by TRIM69
limited our ability to identify whether species variants of TRIM69 possess divergent
antiviral speciﬁcities. Despite this, differential activity was observed as anti-VSIV activity
has apparently been lost in the Mus genus. Whether murine TRIM69s have been
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selected to target other viruses or whether murine orthologs have no antiviral activity
at all remains to be determined.
The lack of anti-VSIV activity conferred by murine TRIM69 could have important
implications for our understanding of how the IFN response constrains VSIV. Many key
VSIV experiments have been conducted in mice (15, 16), and it will be important to
establish in the future whether nonmurine variants of TRIM69 possess anti-VSIV activity
in vivo, potentially limiting the ability of VSIV to invade and colonize certain tissues. It
is possible that the potent inhibition of VSIV observed in vitro will be recapitulated in
vivo. In this way, IFN-induced TRIM69 might inhibit natural VSIV infections and similarly
inﬂuence the safety and/or efﬁcacy of therapeutic interventions (based upon VSIV).
Thus, an improved understanding of how TRIM69 inhibits VSIV may help us to better
understand VSIV pathogenesis and eventually lead to tangible beneﬁts in the clinical
use of VSIV derivatives.
MATERIALS AND METHODS
Cells and viruses. Adherent HEK 293T, BHK-21, BSRT7/5 cells (modiﬁed to stably express T7 RNA
polymerase [62]), NIH 3T3, and Vero cells were propagated from lab stocks maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 9% fetal calf serum (FCS) and 10 g/ml gentami-
cin. CADO-ES1 semiadherent cells were purchased from the DSMZ (ACC 255), and suspension MT4 cells
were expanded from lab stocks and maintained in RPMI medium supplemented with 9% FCS and
10 g/ml gentamicin. C6/36 cells (Aedes albopictus) were propagated from existing lab stocks and
maintained in L-15 (Leibovitz) medium with GlutaMAX, 10% fetal bovine serum, 10% tryptose phosphate
broth, and 1% penicillin-streptomycin (pen/strep). Transduced cells were selected and cultured in
medium additionally supplemented with 2 g/ml puromycin (Melford Laboratories) or 200 g/ml of
hygromycin B (Invitrogen).
The VSIV-GFP virus (rVSVΔG-GFP) competent to undergo a single round of infection but not encoding
the VSV-G envelope (rVSV-ΔG-GFP decorated with VSV-G expressed in trans) system was used (28). Virus
stocks were generated as described previously (42). Brieﬂy, HEK 293T cells were transfected with a VSV-G
expression plasmid. The next day, the cells were infected with rVSV-ΔG-GFP at a multiplicity of infection
(MOI) of 1. Progeny virus-like particle (VLP) stocks were harvested at 24 h postinfection and clariﬁed using
a 0.45-m-pore-size ﬁlter. The replication-competent FL-VSIV-GFP, VSIV, and VSNJV viruses were a
generous gift from Megan Stanifer (Heidelberg University). Virus stocks were generated through infection
of BHK-21 cells using a low MOI. Once cytopathic effect (CPE) was readily apparent, supernatants were
harvested and clariﬁed using a 0.45-m-pore-size ﬁlter.
The D70Y mutant (VSV-P) was made using an Agilent QuikChange Lightning site-directed mutagen-
esis kit, in accordance with the manufacturer’s instructions, using the parental FL-rVSIV-GFP plasmid as
the template [pVSV1()-GFP] (44) and the following oligonucleotides, 5=-GCT TCC GGA TCT GGT ACA
TAC AAG CCT TGA TTG TAT TCA ATT TCT GGT TCA GAT TCT GT-3= and 5=-TGA TTC TGA CAC AGA ATC
TGA ACC AGA AAT TGA ATA CAA TCA AGG CTT GTA TGT ACC AG-3=. The entire coding region was
subsequently sequence veriﬁed to conﬁrm the presence of the sole D70Y (VSV-P) mutation. To rescue the
parental and mutant virus, BSR-T7 cells were seeded and infected with fowlpox T7 virus (equivalent to
an MOI of 2 determined using DF-1 cells) (63). After 1 h of incubation, 1.66 g of the FL-VSIV-GFP
rescue plasmid [pVSV1()-GFP] or mutant D70Y [pVSV1()-GFP P-D70Y] was cotransfected with pBS-N
(0.83 g), pBS-P (0.5 g), and pBS-L (0.33 g) (KeraFAST) using FuGENE6 (Promega). After 48 h,
GFP-positive cells and CPE were observed in the transfected BSR-T7 cells. Supernatant containing VSIV
was harvested and clariﬁed using a 0.45-m-pore-size ﬁlter and stored at 80°C. VSIV was propagated
in BHK-21 cells in T-25 ﬂasks. Cells were infected at a low MOI of VSV harvested from BSR-T7 cells. At 48
h postinfection (or when the majority of cells were GFP positive), supernatant was harvested and clariﬁed
using a 0.45-m-pore-size ﬁlter.
DENV-2 was obtained from Public Health England (catalogue number 0006041v). The NS3 of the
DENV-2 stocks (propagated in Vero cells) used herein was directly sequenced. Brieﬂy, RNA was extracted
from infected cells using the same approaches described below for passaged FL-VSIV-GFP, and the NS3
region was ampliﬁed using the primers 5=-CGA AGA GGA AGA ACA AAT ACT GAC C-3= and 5=-GAT TGT
ACG CCC TTC CAC CTG CTT C-3=; PCR products were sequenced using these primers and an additional
primer (5=-GTG GAG CAT ATG TGA GTG CTA TAG C-3=). The NS3 sequence differed by one amino acid,
a threonine at position 442, from GenBank accession number AAC59275 (strain New Guinea C).
The replication-competent HIV-1 proviral clone NHG (GenBank accession no. JQ585717) and Δenv
derivatives have been described previously (5, 64). Virus stocks were generated through transient
transfection of HEK 293T cells in isolation (NHG) or in conjunction with a VSV-G expression plasmid (NHG
Δenv). The single-cycle HIV-1 lentiviral vector CSGW is a self-inactivating, VSV-G-pseudotyped lentiviral
vector that encodes GFP expressed from an internal spleen focus-forming virus (SFFV) long terminal
repeat (LTR) (65), packaged using GagPol derived from HIV-1 NL4-3 (pNLGP). The single-round RVFV
system has also been described previously (66). Brieﬂy, BHK-Rep cells were transiently transfected with
pCAGGs-M. The cells were washed the following day, and supernatant was harvested at 48 h posttrans-
fection and clariﬁed using a 0.45-m-pore-size ﬁlter.
An NS1-enhanced green ﬂuorescent protein (EGFP) construct expressing inﬂuenza A/Puerto Rico/8/
1934 (H1N1) (PR8) virus was designed based on the previously described Color-Flu system (67). A DNA
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sequence was synthesized (Genewiz) with ﬂanking BsmBI sites corresponding to the NS segment of PR8
(GenBank accession no. EF467817.1) in which the NS1 open reading frame (ORF) had been altered to
code for a C-terminally EGFP-tagged NS1 protein with a CSGG linker. This was immediately followed in
frame by a CSG linker, the 2A protease of porcine teschovirus (PTV), and the nuclear export protein (NEP)
ORF. A splice acceptor site in the NS1 ORF was removed by introducing A527C and A530G (numbering
is in accordance with GenBank accession no. EF467817.1). The sequence was subcloned into the
pHW2000 reverse genetics plasmid. The PR8-NS1-EGFP virus was rescued using a well-established
reverse genetics system previously described (68), a generous gift from Ron Fouchier.
Retroviral vectors and plasmids. The SCRPSY (GenBank accession no. KT368137.1) and doxycycline-
inducible (LKOΔ-MycTagRFP-IP) lentiviral vectors have been previously described (5, 43). The retroviral
vector LHSXN (a gift from T. Zang and P. Bieniasz) is a derivative of LHCX (Clontech) modiﬁed to contain
the multiple-cloning site (MCS) 5=-AAG CTT GGC CGA GAG GGC CGA AAA CGT TCG CGG CCG CGG CCT
CTC TGG CCG TTA AC-3= between the HindIII and HpaI sites (highlighted in italics) of LHCX. All human and
species variants of TRIM69 were synthesized by Genewiz, based on NCBI sequences of the longest
isoform, unless otherwise noted, from the following (GenBank accession no.): human (human isoform A,
NM_182985.4; isoform B, NM_080745.4; isoform C, NM_001301144.1; isoform D, NM_001301145.1;
isoform E, NM_001301146.1), macaque (Macaca Mulatta, XM_015142131.1), rat (Rattus Norvegicus,
BC091171 [clone IRBPp993F0532D, Image ID 7132390; Source Bioscience]), mouse (M. musculus,
BC050815 [clone IRAWp5000E114D, Image ID 6774293; Source Bioscience]; M. caroli, XM_021183811.1;
M. pahari, XM_021193471.1), cow (Bos indicus, XM_019967990.1; edited to change an ambiguity base at
position 547 to a C to match the sequence of Bos taurus, XM_015473308), alpaca (Vicugna pacos,
XM_015237089.1; edited to remove 55 amino acids from the start of the sequence and replace with
ATGGAG [ME] that is found in all other TRIM69 species variants), pig (Sus scrofa, Ensembl no. ENS-
SSCT00000005168; edited to remove a 5= K and replace with ATGGAG [ME]), dog (Canis lupus,
XM_535459.6), ferret (Mustela putorius furo, XM_004751292.2), and horse (Equus caballus,
XM_014733851). Sequences were cloned (using directional SﬁI sites) into pSCRPSY, pLKOΔ-Myc-IP, or
pLHSXN as indicated in the text, ﬁgure, or ﬁgure legend. Human allelic variants were cloned using
overlap extension PCR and the following oligonucleotides: allele 1, 5=-CTC TCT GGC CGA GAG GGC CAT
GGA GGT ATC CAC CAA CCC CTC CAA CAT CGA TCC AGG CAA CTA TGT TGA AAT GAA TGA TTC AAT C-3=,
3=-TGA CCC TGT TGG ATG GCA AGC TCC ATG AAG AAA TGG ACA GCA TCA GAG ATT TGC AG-5=, 5=-GCA
AAT CTC TGA TGC TGT CCA TTT CTT CAT GGA GCT TGC CAT CCA ACA GGG TCA AC-3=, and 3=-TCT CTC
GGC CAG AGA GGC CTT ACT GTG GAT GTA AGA TGT GCA ATG G-5=; allele 2, 5=-CTC TCT GGC CGA GAG
GGC CAT GGA GGT ATC CAC CAA CCC CTC CTC-3=, 3=-TGA CCC TGT TGG ATG GCA AGC TCC ATG AAG
AAA TGG ACA GCA TCA GAG ATT TGC AG-5=, 5=-GCA AAT CTC TGA TGC TGT CCA TTT CTT CAT GGA GCT
TGC CAT CCA ACA GGG TCA AC-3=, and 3=-TCT CTC GGC CAG AGA GGC CTT ACT GTG GAT GTA AGA TGT
GCA ATG G-5=; allele 4, 5=-CTC TCT GGC CGA GAG GGC CAT GGA GGT ATC CAC CAA CCC CTC CTC-3=,
3=-CAG ATG TAG CTT GTT TTC CTT GTG AGC AAC AAT AGC TTC CTT CTG CAT GTT CCT CAG GG-5=, 5=-CCT
GAG GAA CAT GCA GAA GGA AGC TAT TGT TGC TCA CAA GGA AAA CAA GCT ACA TCT GC-3=, and 3=-TCT
CTC GGC CAG AGA GGC CTT ACT GTG GAT GTA AGA TGT GCA ATG G-5=; allele 5, 5=-CTC TCT GGC CGA
GAG GGC CAT GGA GGT ATC CAC CAA CCC CTC CTC-3=, 3=-GTG GAT GGC CCT TGA GTA AGG GTA ACT
TCC TAA TCT CTA CCA ACT TGT CCA GTA CAG-5= 5=-GTA CTG GAC AAG TTG GTA GAG AAG ATT AGG AAG
TTA CCC TTA CTC AAG GGC CAT CCA CAG-3=, and 3=-TCT CTC GGC CAG AGA GGC CTT ACT GTG GAT GTA
AGA TGT GCA ATG G-5=; allele 6, 5=-CTC TCT GGC CGA GAG GGC CAT GGA GGT ATC CAC CAA CCC CTC
CAA CAT CAA TCC AGG CGA CTA TGT TGA AAT GAA TG-3=, and 3=-TCT CTC GGC CAG AGA GGC CTT ACT
GTG GAT GTA AGA TGT GCA ATG G-5=; allele 7, 5=-CTC TCT GGC CGA GAG GGC CAT GGA GGT ATC CAC
CAA CCC CTC CTC-3=, 3=-GAG ACA TTG CTC CTG AAG CTG GCT CAG TTT CAA CTC CAT CTC ATT CAA GGC
TTT C-5=, 5=-GCC TTG AAT GAG ATG GAG TTG AAA CTG AGC CAG CTT CAG GAG CAA TGT CTC TTA GC-3=,
and 3=-TCT CTC GGC CAG AGA GGC CTT ACT GTG GAT GTA AGA TGT GCA ATG G-5=. Allele 4 was used
as a template for allele 5 PCRs, and allele 5 was used as a template for allele 7. The N-terminal fusion of
a mutated uncleavable ubiquitin moiety fused to GFP (Ub-G76VGFP) has been described previously (69).
Plasmid DNA containing Ub-G76VGFP[pcDNA3.1().Ub-G76VGFP], a gift from A. Fletcher, was digested with
BamHI and NotI and inserted into the similarly digested lentiviral vector pCSGWΔNotI (65) (a gift from G.
Towers and A. Thrasher).
Gene editing was achieved using a lentiGuide-Puro system (70) in accordance with the protocols of
the Zhang lab. The following oligonucleotides were used to make TRIM69 guides: 5=-CAC CGC AAC CCT
GTA CTG GAC AAG T-3= and 5=-AAA CAC TTG TCC AGT ACA GGG TTG C-3= (guide 1); 5=-CAC CGA AGA
AGT TAC CCT TAC TCA A-3= and 5=-AAA CTT GAG TAA GGG TAA CTT C-3= (guide 2). Diploid CADO-ES1
cells were either transduced with vectors encoding Cas9 and the relevant TRIM69-targeting sgRNAs or
transduced in parallel with vectors encoding Cas9 and no sgRNA (no guide). Single-cell clones were
generated using limiting dilution, and the KO was conﬁrmed by extracting genomic DNA (DNeasy;
Qiagen), followed by PCR ampliﬁcation of the guide target regions in exon 2 using the following
oligonucleotides 5=-CAC TTT CAA AGG AGA GAT TAT GTG C-3= and 5=-GAG CAG TCT GGG CTT TCT AAT
CAT C-3=. The PCR products were cloned into pGEM-T-Easy (Promega), and multiple clones were Sanger
sequenced.
Viral vectors were produced using transient transfection of HEK 293T cells (5 g of vector/genome
plasmid, 5 g of the relevant GagPol expression vector, and 1 g of a VSV-G expression plasmid).
Vector-containing supernatants were ﬁltered (using a 0.45-m-pore-size ﬁlter) and used to transduce the
relevant cell types.
To make the NS3 expression plasmids, the NS3 coding sequence from the DENV-2 New Guinea C
strain (nucleotides 6376 to 6756 of GenBank accession no. KM204118.1) was synthesized (Genewiz) with
TRIM69 Inhibits VSIV Journal of Virology
October 2019 Volume 93 Issue 20 e00951-19 jvi.asm.org 17
 o
n
 O
ctober 28, 2019 at SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
a 5= ATG, ﬂanked by 5= HindIII and 3= XbaI sites, and subcloned into pcDNA 3.1(). The K104R mutation
(AAA ¡AGA) was introduced using Agilent’s QuikChange Lightning Mutagenesis kit and the following
primers: 5=-GAC GGC TCT TGG ATT TCT TCC AGG CTC CAA TGC-3= and 5=-GCA TTG GAG CCT GGA AGA
AAT CCA AGA GCC GTC-3=.
Arrayed ISG expression screening. The ISG screens were executed as described previously (5, 27).
Brieﬂy, MT4 cells were seeded in 96-well plates and transduced with ISG-encoding SCRPSY vectors (one
ISG per well). At 48 h posttransduction, cells were infected with VSIV-GFP. Following incubation
overnight, cells were ﬁxed and analyzed using ﬂow cytometry.
Western blotting. For preparation of cell lysates, cell pellets were resuspended in SDS sample buffer
(12.5% glycerol, 175 mM Tris-HCl [pH 8.5], 2.5% SDS, 70 mM 2-mercaptoethanol, 0.5% bromophenol
blue). Proteins were subsequently separated on NuPage 4% to 12% Bis-Tris polyacrylamide gels and
transferred onto nitrocellulose membranes. Blots were probed with either anti-actin (JLA20 hybridoma;
courtesy of the Developmental Studies Hybridoma Bank, University of Iowa), one of two anti-TRIM69
antibodies (catalog no. ab111943 [Abcam] or PA5-12215 [Thermo Fisher]), anti-DENV-2 NS3 (PA5-32199;
Thermo Fisher), anti-phospho-STAT1 (Tyr701) (58D6), or anti-c-myc (9E10 hybridoma; Developmental
Studies Hybridoma Bank, University of Iowa). Thereafter, membranes were probed with DyLight-labeled
goat secondary antibodies (Thermo) and scanned using a LiCor Odyssey scanner.
Virus infections and titrations. For assays using GFP-encoding viruses, cells were seeded in 96-well
plates. Adherent and semiadherent cells were seeded 24 h before challenge or treatment whereas
suspension cells were seeded immediately prior to infection or treatment. In experiments using
doxycycline-inducible TRIM69 expression, cells were treated with 125 ng/ml of doxycycline hyclate
(Sigma) 24 h before infection. Where stated in the ﬁgures, ﬁgure legends, or text, cells were treated with
2 M ruxolitinib (INCB018424) (catalog no. S1378-SEL; Stratech), 50 nM bortezomib (2204; Cell Signaling
Technology), or 1,000 units of IFN- (11420-1; PBL Assay Science) immediately before infection (or in the
case of IFN-, 24 h before infection, except for the experiments in Fig. 8, where a 4-h treatment was
used). Cells were then infected with titrated challenges of the indicated virus and incubated overnight
(16 h) or for 48 h (HIV-1 and RVFV) prior to ﬁxation using 4% formaldehyde and enumeration of
infected GFP-positive cells using ﬂow cytometry.
For quantiﬁcation of focus-forming units (FFUs), Vero cells were seeded in 96-well plates. The
following day, cells were pretreated with IFN- (24 h at 1,000 U/ml) prior to infection with FL-VSIVGFP
or DENV-2 propagated in Vero cells (mammalian) or C6/36 cells (insect). Cells were infected with titrated
DENV-2 in DMEM (2% FCS) for 1 h prior to overlay with DMEM (5% FCS, 0.8% carboxymethylcellulose).
Forty-eight hours later, cells were ﬁxed (methanol) and permeabilized (0.1% Triton X-100; Fisher). FFUs
were visualized using MAB8705 anti-dengue virus complex antibody clone D3-2H2-9-21 (Millipore) and
goat anti-mouse Alexa Fluor 488 (A-11001; Thermo Fisher), as described previously (71). As a control,
serially diluted FL-VSIV-GFP was examined in parallel and ﬁxed in 4% formaldehyde following overnight
incubation (16 h). The number of ﬂuorescent foci of immunostained DENV-2- and VSIV-infected cells
was enumerated using a Celigo imaging cytometer (Nexcelom Bioscience).
For 50% tissue culture infective dose (TCID50) assays, MT4 cells were seeded in 96-well plates and
treated with 125 ng/ml of doxycycline hyclate (Sigma) 24 h prior to infection. The cells were infected with
eight replicates of 3-fold serially diluted full-length VSNJV or VSIV. At 72 h postinfection (hpi), CPE was
analyzed, and the TCID50 was calculated using the Spearman and Kärber algorithm and a modiﬁed TCID50
calculator from Marco Binder.
DENV-2 NS3 transfections. HEK 293T cells were transduced with either SCRPSY-empty or SCRPSY-
TRIM69 and seeded in six-well plates before transfection with 2 g of pcDNA (either empty, wild-type
DENV-2 NS3, or DENV-2 NS3 K104R mutant). At 48 h posttransfection, cells were lysed in 500 l of SDS
sample buffer. In parallel, 293T cells transduced with SCRPSY-empty and SCRPSY-TRIM69 were chal-
lenged with serially diluted VSV-GFP to demonstrate TRIM69 activity.
VSIV in vitro evolution, RNA extraction, PCR, and sequencing. MT4 cells expressing TRIM69 were
seeded and induced with doxycycline hyclate (200 ng/ml) 24 h prior to challenge with FL-VSIV-GFP at a
low MOI (1% infection following 16 h of incubation). The level of infection based on the percentage
of GFP-positive cells was monitored daily. Once the culture was overwhelmed, supernatant was ﬁltered
(0.45-m pore size) and used to infect a second culture. Following passage 2, CPE was observed at 24
h postinfection (in the presence of TRIM69). The supernatant of the passaged virus was ﬁltered (0.45-m
pore size) and stored. Cell pellets were resuspended in TRIzol (Invitrogen), and viral RNA was isolated
from infected cells using a hybrid TRIzol and RNeasy extraction (Qiagen) protocol. Viral cDNA was reverse
transcribed (SuperScript III) using random hexamer primers. All VSIV coding regions were PCR ampliﬁed,
and the PCR products were directly sequenced using Sanger sequencing (Euroﬁns Genomics).
Sequence collection, alignment, and expression analysis. TRIM69 sequences were obtained from
publicly available databases such as ENSEMBL and GenBank using TBLASTN (72). The protein sequences
were aligned using MAFFT (73), and a codon alignment was generated based on the protein alignment
using PAL2NAL (74). The alignment was screened for recombination in HyPhy (75) using single-
breakpoint recombination (SBP) and GARD, a genetic algorithm for recombination detection (76). TRIM69
expression in primary human ﬁbroblasts was meta-analyzed from published data (1), and counts per
million (CPM) of TRIM69 expression were extracted as described previously (1). TRIM69 expression levels
in human cells were assessed by meta-analyzing existing gene expression data through the EMBL-EBI
Expression atlas (https://www.ebi.ac.uk/gxa/home), leading to the selection of CADO-ES1 cells for TRIM69
knockout.
To explore the amino acid variation surrounding amino acid D70, 50 sequences from NCBI were
aligned, and identical sequences were removed from the alignment to produce a nonredundant set of
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protein sequences. A WebLogo sequence logo (77) for the protein region was produced using a web
server (https://weblogo.berkeley.edu/).
Phylogenetics and positive selection analyses. The best substitution model was selected using
Bayesian information criteria (BIC) in jModeltest (78), and the maximum likelihood phylogeny was
reconstructed with this model in PhyML with 1,000 bootstrap replicates (79). The primate lineage of the
gene tree, which is more extensively sampled for species, was used in CODEML (40) to detect sites under
positive selection.
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